Yuzuru Tamaru1, Shiro Oka2,3, Shinji Tanaka4, Shinji Nagata5, Yuko Hiraga6, Toshio Kuwai7, Akira Furudoi8, Tadamasa Tamura9, Masaki Kunihiro10, Hideharu Okanobu11, Koichi Nakadoi12, Hiroyuki Kanao13, Makoto Higashiyama14, Koji Arihiro15, Kazuya Kuraoka16, Fumio Shimamoto17, Kazuaki Chayama1. 1. Department of Gastroenterology and Metabolism, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. 2. Department of Gastroenterology and Metabolism, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. oka4683@hiroshima-u.ac.jp. 3. Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan. oka4683@hiroshima-u.ac.jp. 4. Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan. 5. Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan. 6. Department of Endoscopy, Hiroshima Prefectural Hospital, Hiroshima, Japan. 7. Department of Gastroenterology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan. 8. Department of Gastroenterology, JA Hiroshima General Hospital, Hiroshima, Japan. 9. Department of Internal Medicine, Hiroshimakinen Hospital, Hiroshima, Japan. 10. Department of Internal Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. 11. Department of Gastroenterology, Chugoku Rosai Hospital, Kure, Japan. 12. Department of Gastroenterology, JA Onomichi General Hospital, Onomichi, Japan. 13. Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan. 14. Department of Gastroenterology, Shobara Red Cross Hospital, Shobara, Japan. 15. Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan. 16. Department of Anatomical Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan. 17. Faculty of Humanities, Hiroshima Shudo University, Hiroshima, Japan.
Abstract
BACKGROUND: We aimed to clarify the long-term outcomes of patients with T1 colorectal carcinoma (CRC) after endoscopic resection (ER) and surgical resection. METHODS: We examined T1 CRC patients treated during 1992-2008 and who had ≥5 years of follow-up. Patients who did not meet the curative criteria after ER according to the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines were defined as "non-endoscopically curable" and classified into three groups: ER alone (Group A: 121 patients), additional surgery after ER (Group B: 238 patients), and surgical resection alone (Group C: 342 patients). Long-term outcomes and predictors of recurrence were analyzed. RESULTS: Of the 882 patients with T1 CRC, 701 were non-endoscopically curable. Among these patients, recurrence and 5-year overall survival (OS) rates were 0.6 and 91.1%, respectively. In Groups A, B, and C, recurrence rates were 5.0, 5.5, and 3.8%, OS rates were 79.3, 92.4, and 91.5% (p < 0.01), and 5-year disease-free survival (DFS) rates were 98.1, 97.9, and 98.5%, respectively. Thirty-two patients experienced local recurrence or distant/lymph node metastasis (Group A: 6; Group B: 13; Group C: 13) and 14 patients died of primary CRC (Group A: 3; Group B: 7; Group C: 4). Age ≥65 years, protruded gross type, positive lymphatic invasion, and high budding grade were significant predictors of recurrence in non-endoscopically curable patients. CONCLUSIONS: Our findings supported the JSCCR criteria for endoscopically curable T1 CRC. ER for T1 CRC did not worsen the clinical outcomes of patients who required additional surgical resection.
BACKGROUND: We aimed to clarify the long-term outcomes of patients with T1 colorectal carcinoma (CRC) after endoscopic resection (ER) and surgical resection. METHODS: We examined T1 CRC patients treated during 1992-2008 and who had ≥5 years of follow-up. Patients who did not meet the curative criteria after ER according to the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines were defined as "non-endoscopically curable" and classified into three groups: ER alone (Group A: 121 patients), additional surgery after ER (Group B: 238 patients), and surgical resection alone (Group C: 342 patients). Long-term outcomes and predictors of recurrence were analyzed. RESULTS: Of the 882 patients with T1 CRC, 701 were non-endoscopically curable. Among these patients, recurrence and 5-year overall survival (OS) rates were 0.6 and 91.1%, respectively. In Groups A, B, and C, recurrence rates were 5.0, 5.5, and 3.8%, OS rates were 79.3, 92.4, and 91.5% (p < 0.01), and 5-year disease-free survival (DFS) rates were 98.1, 97.9, and 98.5%, respectively. Thirty-two patients experienced local recurrence or distant/lymph node metastasis (Group A: 6; Group B: 13; Group C: 13) and 14 patients died of primary CRC (Group A: 3; Group B: 7; Group C: 4). Age ≥65 years, protruded gross type, positive lymphatic invasion, and high budding grade were significant predictors of recurrence in non-endoscopically curable patients. CONCLUSIONS: Our findings supported the JSCCR criteria for endoscopically curable T1 CRC. ER for T1 CRC did not worsen the clinical outcomes of patients who required additional surgical resection.
Authors: Alexander Rickert; Rustam Aliyev; Sebastian Belle; Stefan Post; Peter Kienle; Georg Kähler Journal: Gastrointest Endosc Date: 2014-01-09 Impact factor: 9.427
Authors: S Tanaka; K Haruma; C R Teixeira; S Tatsuta; N Ohtsu; Y Hiraga; M Yoshihara; K Sumii; G Kajiyama; F Shimamoto Journal: J Gastroenterol Date: 1995-12 Impact factor: 7.527
Authors: A Overwater; K Kessels; S G Elias; Y Backes; B W M Spanier; T C J Seerden; H J M Pullens; W H de Vos Tot Nederveen Cappel; A van den Blink; G J A Offerhaus; J van Bergeijk; M Kerkhof; J M J Geesing; J N Groen; N van Lelyveld; F Ter Borg; F Wolfhagen; P D Siersema; M M Lacle; L M G Moons Journal: Gut Date: 2016-11-03 Impact factor: 23.059
Authors: Thomas E Read; Matthew G Mutch; Benjamin W Chang; Michael S McNevin; James W Fleshman; Elisa H Birnbaum; Robert D Fry; Philip F Caushaj; Ira J Kodner Journal: J Am Coll Surg Date: 2002-07 Impact factor: 6.113
Authors: D E Fleischer; S B Goldberg; T H Browning; J N Cooper; E Friedman; F H Goldner; E B Keeffe; L E Smith Journal: JAMA Date: 1989-01-27 Impact factor: 56.272